This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MarketVIEW: Hepatitis A Vaccines (Emerging/ROW)

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

MarketVIEW: Hepatitis A vaccines (Emerging/ROW)

Hepatitis A (HAV) produces a self-limiting liver disease which can produce a range of symptoms such as nausea, anorexia, fever, malaise or abdominal pain. Unlike Hepatitis B and C viruses it does not cause a long term chronic infection although it can manifest itself as prolonged or relapsing disease for up to six months. The HAV virus is transmitted by person-to-person transmission through the fecal-oral route sometimes in outbreaks to due ingestion of contaminated food. Many countries in Africa, LATAM and SE Asia have high or intermediate endemnicity for HAV. 

The Hepatitis A vaccine is highly effective at preventing HAV infection and is now recommended for all children at age 1 year in the United States and other selected countries which have added the vaccine as part of a national immunization program (NIP). The HAV vaccine is also widely used in the travelling population to high or intermediate endemic countries. 

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential (value/volume) of HAV vaccines in 35 countries in the "Emerging" or Rest of World region (ROW) to 2030. The model takes into account expected new NIPs, probable "catch-up" campaigns and expansion of private sector use in selected age groups. A detailed executive presentation is also included outlining all model outputs, assumptions and a country-by-country review of epidemiological dynamics and vaccination policy.

THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL Contents – Executive presentation (MS PowerPoint based)Author's noteExecutive summaryCommercial model – key outputsHAV monovalent vaccine(s): available market (€ 000s) to 2030HAV monovalent vaccine(s): available volume (€ 000s) to 2030HAV monovalent vaccine(s): BRIC-MT markets (€ 000s) to 2030HAV monovalent vaccine(s): BRIC-MT volume (000s) to 2030HAV monovalent vaccine(s): available market(s) (€ 000s) to 2030Hepatitis A virus: Review of current epidemiologyGlobal epidemiology: seroprevalenceGlobal epidemiology: seroprevalence (cont..)Global epidemiology: incidenceUS: incidenceEurope: incidence5EU overview: incidenceOther high-income countries: incidenceTrends in incidence rates (low endemicity countries)BRIC-M: incidenceOther LATAM: epidemiologySoutheast Asia overviewHong KongSingaporeTaiwanMalaysiaPhilippinesThailandSouth KoreaMongoliaNepalHAV epidemiology summaryHepatitis A virus vaccines: Key model assumptionsPopulations modelledOverview of modeling strategy: new infant NIPsOverview of modeling strategy: private adult segmentOverview of modeling strategy: at risk populationNational HAV vaccine policiesPopulations modelled: at risk populationCommercial model assumptions: Infant, publicCommercial model assumptions: Infant, public (cont..)BibliographyDisclaimerAbout VacZine AnalyticsPAGES: 65 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model(s) (MS Excel-based)Title sheetNotesCHARTS – VALUE (total)CHARTS – VOLUME (total)WPR summaryCountry value summary (Total)Public vs private value summaryValue adult (priv)Value infant (priv)Value preschool (priv)Value infant (pub)Value adult (pub)Global price summaryVolume adult (priv)Volume infant (priv)Volume preschool (priv)Volume infant (pub)Volume adult (pub)Country worksheetsChina (infants)S Korea (infants) Israel (infants) Australia (infants) Argentina (infants) Panama (infants) Paraguay (infants) Uruguay (infants) Taiwan (infants) Russia (infants) Kazakhstan (infants) India (infants) Ukraine (infants) Brazil (infants) Turkey (infants) Mexico (infants) Peru (infants) Venezuela (infants) Columbia (infants) Chile (infants) Guatemala (infants) Saudi Arabia (infants)Other Middle East (infants) Belarus (infants) Hong Kong (infants) Malaysia (infants) Thailand (infants) Vietnam (infants) Nepal (infants) Pakistan (infants) Philippines (infants) Mongolia (infants) Pakistan (infants) Pakistan (infants) Pakistan (infants) Japan (infants)Sheets repeated for adults, preschoolersPopulation databasesScenarios"at risk" populationsUrban populations% privateHBV coverage: case studiesEpidemiologyIncome groupsWorld PopulationBack pageWORKSHEETS = 110

To order this report:: MarketVIEW: Hepatitis A vaccines (Emerging/ROW)

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs